Kodiak Sciences Overview
Latest ROE for Kodiak Sciences: -200.31% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-200.31%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Kodiak Sciences (KOD) currently reports a ROE of -200.31%. That is below the Healthcare sector average of 20.86%. Use the charts on this page to explore Kodiak Sciences's ROE history and peer comparisons.
Kodiak Sciences's ROE of -200.31% is lower than the Healthcare sector average of 20.86%. That is roughly 1060.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Kodiak Sciences's current -200.31% should be judged against Healthcare norms (sector average: 20.86%) and against KOD's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -200.31%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.86%. From there, open related valuation or income-statement pages for Kodiak Sciences, and consider following KOD for alerts when major investors trade the stock.
Kodiak Sciences is classified in the Healthcare sector. On ROE, it currently shows -200.31% versus a sector average near 20.86%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KOD with unrelated industries.
